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ABSTRACT
Protein-tyrosine phosphatases (PTPases) have a catalytic
cysteine residue whose reduced state is integral to the reaction
mechanism. Since exposure to air can artifactually oxidize this
highly reactive thiol, PTPase assays have typically used potent
reducing agents to reactivate the enzymes present; however,
this approach does not allow for the measurement of the
endogenous PTPase activity directly isolated from the in vivo
cellular environment. Here we provide a method for using an
anaerobic chamber to preserve the activity of the total PTPase
complement in a tissue lysate or of an immunoprecipitated
PTPase homolog to characterize their endogenous activation
state. Comparison with a sample treated with biochemical
reducing agents allows the determination of the activatable
(reducible) fraction of the endogenous PTPase pool.
INTRODUCTION
Dozens of enzyme homologs in the protein-tyrosine
phosphatase (PTPase) superfamily have been cloned and
characterized over the past decade (1). The unifying structural
feature among PTPases, is a conserved ~230 amino acid
domain that contains the characteristic sequence motif,
(I/V)HCXAGXGR(S/T)G, with the cysteine residue that
catalyzes protein phosphotyrosine hydrolysis by the formation
of a cysteinyl-phosphate intermediate (2). The catalytic
cysteine residue must be present in an unconjugated,
unoxidized state to carry out phosphotyrosine hydrolysis. Thus,
cellular and environmental reactions that lead to the oxidation
or modification of this site will effectively block the enzyme's
catalytic activity and reduce the specific activity of the cellular
PTPase pool (2,3).  Since alterations in the oxidation state of
the catalytic cysteine within the cellular environment has
profound effects on the PTPase specific activity, attention has
recently been focused on how the redox state of the catalytic
thiol is regulated in vivo. Crystallographic studies have shown
that this thiol moiety is in spatial proximity to amino acid side
chains adjacent to the enzyme active site that strongly affect its
ionization (4). These interactions enhance the reactivity of the
cysteine thiol group and effectively lowers its pKa to more than
3 units below that found in a typical free cysteine thiol or
protein cysteine side chains. Thus, at physiological pH, the
catalytic cysteine is ionized as a thiolate anion which is easily
derivatized or oxidized in preference to other neighboring
sulfhydryls (3,5).
One method to directly assess the reversible oxidation of thiol-
dependent cellular enzymes, including PTPases, is to work
under a neutral atmosphere. We have recently demonstrated
that from a variety of tissue sources, PTPases are sensitive to
oxidation by exposure to air when working with cell lysates on
the benchtop (6). Frequently, reduction of the PTPases present
in a cell lysate by biochemical treatment with strong reducing
agents is incomplete, preventing an accurate assessment of
both the endogenous level of PTPase activity, as well as the
fraction of the PTPase pool that is reversibly oxidized or
conjugated. Working within an anaerobic chamber allows for
the measurement of endogenous PTPase levels, and including a
biochemical reductant in the assay buffer allows for the
measurement of the reducible pool of PTPase in the sample.
This technique is useful for assay of cellular lysates or
immunoprecipitated enzymes where specific antibodies are
available.
MATERIALS AND METHODS
Cell culture media and sera were obtained from Cellgro
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(Herndon, VA). Para-nitrophenylphosphate (pNPP) and
reduced, carboxymethylated-maleylated (RCM)-lysozyme
were obtained from Sigma. γ-[
32P]-ATP was from Amersham
Pharmacia Biotech (Piscataway, NJ). Monoclonal PTP1B
antibody (Ab-2) was from Calbiochem/Oncogene Sciences (La
Jolla, CA). Trisacryl protein G was obtained from Pierce
(Rockford, IL). The BBL GasPak Disposable Anaerobic
Indicator, #4370504 was purchased from Becton Dickinson,
(Sparks, MD). All other reagents were obtained from Sigma
Chemical (St. Louis, MO) or Fisher Scientific (Pittsburgh, PA).
Cell Culture
3T3-L1 pre-adipocytes were maintained in Dulbecco's
modified Eagle's medium (DMEM) / Ham's F12 medium (1:1)
supplemented with 10% (v/v) fetal calf serum. Adipocyte
differentiation was induced at 2 days post confluence with
medium supplemented with 100 nM insulin, 0.25 µM
dexamethasone, and 0.5 mM isobutylmethylxanthine (IBMX).
After 2 days, dexamethasone and IBMX were removed from
the medium and the cells were allowed to differentiate further
for an additional 6 days. Prior to use, the cells were serum-
starved in medium containing 0.1% (w/v) bovine serum
albumin (BSA) for 16 hours. Human HepG2 cells were
maintained in Eagle's Minimal Essential Medium (EMEM)
supplemented with 10% (v/v) fetal calf serum and 1X each of
non-essential amino acids and L-glutamine (Cellgro). Cells
were used at 80% confluence, after 16 hours of serum
starvation in medium containing 0.5% (w/v) BSA.
Preparation of Cell Lysates
Cells are lysed by homogenization in ice-cold homogenization
buffer (150 mM NaCl, 5 mM EDTA, 5 mM EGTA, in 50 mM
Hepes, pH 7.5, containing a protease inhibitor cocktail
(Sigma), with brief sonication. Prior to use, all buffer solutions
are deoxygenated within the chamber by stirring overnight.
Anaerobic Chamber and Experimental
Conditions
An enclosed anaerobic work station (Forma Scientific, model #
901024) was used to provide an oxygen-free environment for
cell and tissue homogenization and anaerobic PTPase assay.
The use of this chamber is detailed in the Protocol section. This
chamber uses palladium catalyst wafers and desiccant wafers to
maintain strict anaerobiosis to less than 10 ppm O2 (according
to the specifications provided by the manufacturer). High
purity N2 is used for purging the chamber initially and the
working anaerobic gas mixture was N2:H2:CO2 proportioned at
85:10:5. Monitoring the O2 concentration to identify possible
air leaks while working in the chamber is performed using a
BBL GasPak Disposable Anaerobic Indicator which changes
color when the O2 concentration reaches 0.5% (~ 5000 ppm).
For anaerobic conditions, the tissue samples and cultured cells
were introduced into the chamber in a frozen state and
disrupted as described above into deoxygenated
homogenization buffers.
Following appropriate cell treatment with various hormones,
cytokines or other reagents, the dish is snap-frozen by pouring
on a layer of liquid nitrogen. Once the nitrogen has evaporated,
the dishes are introduced into the chamber in a frozen state
according to the detailed protocol discussed below.
PTPase Enzyme Activity Using pNPP as
Substrate
Aliquots containing an appropriate amount of cell fraction
protein are incubated in a final volume of 100 µl at 30°C for
cell lysates or 37°C for immunoprecipitated enzymes, for 10-
120 min in reaction buffer containing 10 mM pNPP and 2 mM
EDTA in 20 mM 2-(N-morpholino)ethanesulfonic acid (MES)
at pH 6.0, with and without 2 mM DTT. The reaction was
stopped by the addition of 900 µl of 0.2 M NaOH and the
absorption was determined at 410 nm (7). The initial rate of
pNPP hydrolysis was estimated from the linear portion of the
earliest time points of the enzymatic reaction.
PTPase Enzyme Activity Using [
32P]-RCM-
Lysozyme as Substrate
Alternatively, RCM-lysozyme can be used as a more specific
PTPase substrate. Recombinant human insulin receptors from
transfected CHO cells (8) or commercially available were
partially purified on wheat germ lectin-agarose (Vector
Laboratories, Burlingame, CA) as described (9). RCM-
lysozyme was radioactively labeled on tyrosine by
phosphorylating with the insulin receptor preparation and γ-
[
32P]-ATP (10). The reaction was initiated with the addition of
0.5 mg of RCM-lysozyme and incubated at 25°C for 16 hrs.
The reaction was terminated with the addition of trichloroacetic
acid (TCA) to a final concentration of 20% (w/v) and
centrifuged at 30,000 x g for 15 min at 4°C. The pellet was
washed 3 times with 20% TCA and dialyzed against 50 mM
imidazole-HCl, pH 7.2.
PTPase activity was assayed using the indicated amount of cell
fraction protein at 30°C for cell lysates or 37°C for
immunoprecipitated enzymes, for 10-120 min in reaction
buffer containing 50 mM HEPES, pH 7.0 and 2 mM EDTA,
with and without 2 mM DTT. The reaction was initiated by the
addition of 20 µl of [
32P]-phosphotyrosyl RCM-lysozyme
(~20,000 dpm) and terminated by the addition of 0.9 ml of
acidic charcoal mixture, consisting of 0.9 M NaCl, 90 mM
sodium pyrophosphate, 2 mM NaH2PO4 and 4% (w/v) Norit A
activated charcoal (11). After centrifugation in a microfuge, the
amount of radioactivity in 0.4 ml of supernatant was measured
by Cerenkov counting in a liquid scintillation counter. The
initial rate of RCM-lysozyme hydrolysis was estimated from
the linear portion of the earliest time points of the enzymatic
reaction where less than 20% of the RCM-lysozyme was
hydrolyzed during the 30 minute reaction period.Zhu and Goldstein 3
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RESULTS
Assay of overall PTPase activity in cell or tissue lysates. We
have evaluated this method using differentiated 3T3-L1
adipocytes. Cells were snap frozen with liquid nitrogen and
transferred into the chamber for assay. Cells were lysed within
the chamber environment into deoxygenated buffers and
lysates were withdrawn from the chamber using tightly-capped
sealed tubes for centrifugation. The enzyme assay was
performed within the chamber using pNPP as substrate.
Cell lysis on the benchtop under aerobic conditions resulted in
a 27% reduction in PTPase activity (P<0.001) in the crude
homogenates measured in the absence of added reducing
agents (Fig. 1). When PTPase activity was measured in the
presence of DTT, we detected no significant change in the
activity as measured in the chamber. However, the activity that
had been inhibited by air exposure was restored by treatment
with DTT to the level found when samples were maintained in
the anaerobic chamber (Fig. 1).
Fig. 1: Effect of air exposure on PTPase activity in lysates
of 3T3-L1 adipocytes and reversibility with DTT. 3T3-L1
adipocytes were differentiated as described in Methods and
individual 10-cm dishes were snap-frozen with liquid nitrogen.
Replicate dishes were then introduced into the anaerobic
chamber in the frozen state and disrupted into deoxygenated
buffers or homogenized into the same buffer on the bench top
in air. Samples containing 30 µg protein were then subjected to
the pNPP assay in the presence or absence of 2 mM DTT as
described. PTPase activity (µmol min
-1 mg
-1) is calculated from
the A410 of the samples following a 10 min incubation using a
molar extinction coefficient of 1.78 x 10
4 M
-1 cm
-1  (7).
Modified from reference 6 and reproduced with permission.
We also evaluated whether the catalytic activity of PTP1B, a
specific cellular PTPase enzyme immunoprecipitated from
HepG2 cells was altered by exposure to air (Fig. 2). The
measurement of PTP1B-specific activity was facilitated by
using a monoclonal antibody to PTP1B that can immunoadsorb
the enzyme in a catalytically active state. To maintain the
endogenous reduced state of the enzyme thiol, all stages of the
immunoprecipitation process, including centrifugation,
washing of the pellets, and the assay itself were performed
under strict nonoxidizing conditions. The activity of PTP1B
was reduced dramatically by air exposure to 36% of the level
observed in the samples maintained under anaerobic conditions
throughout the experiment within the chamber environment
(P< 0.001).
Fig. 2: Effect of air exposure and in vitro oxidation and
reduction reactions on the catalytic activity of PTP1B.
Following a preclearing step, PTP1B was immunoprecipitated
from lysates of snap-frozen HepG2 cells either within the
anaerobic chamber environment or on the bench top in air, as
described in Materials and Methods. The immunoprecipitated
samples were washed, and PTPase activity was assayed by
using  pNPP as substrate. A comparison between PTP1B
activity under aerobic vs. anaerobic conditions is shown.
PTPase activity is presented as µmol min
-1 mg
-1
immunoprecipitated cell lysate. Modified from reference 6 and
reproduced with permission.
DISCUSSION
PTPases are highly active enzymes with high turnover rates,
and their activity in the cell must be attenuated for signal
transduction mechanisms involving protein tyrosine
phosphorylation to proceed in a balanced manner (12).
Recently, several laboratories have provided evidence for novel
regulatory mechanisms involving reactive oxygen species,
especially H2O2, which can oxidize and inactivate PTPase
enzymes in a stepwise fashion (13-15). The regulation of
PTPase catalytic activity by reactions involving the catalytic
cysteine is emerging as a key mode for suppression of these
enzymes in signal transduction by hormones and cytokines in
the cell (16-17).
This methodology can be used to assay the total PTPase
activity in lysates of various cells and tissues from different
sources as well as following treatments with hormones or
cytokines. Cells are stabilized by snap-freezing with liquidZhu and Goldstein 4
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nitrogen and transferred into the chamber for assay. Handling
of the samples within the chamber can maintain the state of
enzyme reduction and activation from the time of isolation.
Samples can also be withdrawn from and reintroduced into the
chamber keeping the samples within the confines of tightly-
capped O-ring sealed tubes for various experimental
manipulations, such as centrifugation or incubations with
reagents that require refrigerated temperatures.
Sample assay in the absence or presence of added dithiothreitol
provides a means of directly evaluating the proportion of
endogenous enzyme activity that can be reactivated by
biochemical reduction. The reactivated activity fraction
represents enzyme forms that are partially oxidized by
intracellular reactions with reactive oxygen species as well as
artifactually by air exposure (Fig. 3).
Fig. 3: Some oxidative structural modifications of the
PTPase catalytic site that occur in vivo.
The catalytic thiol of PTPases is susceptible to a variety of
inactivating modifications. These include oxidation in a
stepwise fashion to progressively more inert forms (13-15).
The catalytic cysteine thiol is first oxidized to the sulfenic
(-SOH) form, which is amenable to reduction by cellular
enzymatic mechanisms or with reducing agents in vitro,
followed by further sequential steps of oxidation, to sulfinic
(-SO2H) and sulfonic (-SO3H) forms, leading to irreversible
PTPase inactivation. Also, the reduced, ionized cysteine thiol,
or a partially oxidized form is susceptible to conjugation with
glutathione, which provides an inactive, but potentially
reactivatable form of the enzyme (22).
Our laboratory has been interested in studying PTPases, in
particular characterizing their role in the regulation of the
insulin action pathway (18). The intracellular PTPase PTP1B,
has emerged as a key regulator of insulin signaling and is a
target of inhibition for the potential treatment of type 2 diabetes
mellitus (19). PTP1B is the target of an oxidant signal
generated by the action of EGF and other growth factors (17).
Insulin also generates a cellular oxidant burst that appears to be
coupled to the oxidative inhibition of PTP1B in insulin-
sensitive cell types (20,21).
In summary, we describe the use of a commercially available
anaerobic chamber system to evaluate the endogenous level of
PTPase activity from various cell and tissue sources (6). Since
cellular PTPases, as well as other enzyme systems that may be
susceptible to oxidation-reduction reactions, are susceptible to
oxidative inhibition by air exposure, the use of the anaerobic
chamber methodology provides an important advantage for
enzyme characterization. Evaluation of the changes in the
activation state of cellular PTPases from endogenous sources
has recently provided additional evidence for modulation of the
activation state of this important class of regulatory enzymes
within the cellular milieu in response to changes in the
abundance of cellular reactive oxygen species and other thiol
side-chain reactions, including glutathione conjugation. This
approach is widely adaptable to the characterization of
regulation of thiol reactivity in determining the catalytic
activity of cellular PTPases and how this process impacts on
signal transduction by reversible protein-tyrosine
phosphorylation.
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PROTOCOLS
Annotated from Model 1025/1029 Anaerobic System Installation and Operation Manual, Manual No. 7011025, Revision 2, Forma
Scientific, Inc., PO Box 649, Marietta, OH 45750.
Anaerobic manipulation procedures
General information
1.  The anaerobic work station (model #901024) was purchased from Forma Scientific, Marietta, OH.
2.  High-purity N2 for purging and the working anaerobic gas mixture (N2:H2:CO2=85:10:5) from a reliable commercial
source.
3.  The anaerobic environment inside the chamber should be monitored with O2 indicator strips (BBL strips, Becton
Dickinson and company) prior to and during experiments. The strips will react if the ambient O2 concentration is more
than 0.5% in the chamber.
4.  Buffer solutions and equipment introduced into the chamber need to be deoxygenized overnight prior to use in
experiments.
Installation of charcoal, catalyst and desiccant activated wafers, and the chamber relief bubbler
1.  Open the air filter system door in the top center of the right side wall.
2.  Slide the wafers into the correct slots, charcoal on top, palladium catalyst wafer in the middle and desiccant wafer at the
bottom.
3.  The palladium catalyst wafers and desiccant wafers need to be regenerated by heating 160
oC for two hours weekly, and
can be reused for one year. The charcoal activated filter needs to be replaced every 6 months.
4.  To prepare the chamber relief bubbler, fill the glass bottle shipped with the unit, with mineral oil to a level of
approximately 1-1/2 inches. Clip the bottle into the chamber relief with the tubing extending approximately 1/8 inches in
the mineral oil.
5.  Change the mineral oil once a month and clean the bottle. Check the bottle daily to ensure that the tube extends into the
mineral oil.
Preparation of anaerobic environment for the first use, operation of the interchange device both automatically
and manually, are performed exactly as described in the manual.
Initial settings:
1.  Gas system switch → on.
2.  Catalyst fan switch → on.
3.  Light switch → on.
4.  Vacuum, nitrogen, and equalize switch → auto.
5.  Manual fill knob → off.
Deoxygenation of solutions:
1.  Open the outer door with the inner door closed.
2.  Put the solution in a baker with stir bar and other related material into the exchanger.
3.  Close the outer door.
4.  Press the start cycle button to run one or more degas cycles automatically or run manually.
5.  Open the inner door and transfer the items into the glove chamber.
6.  Close the inner door.
7.  Put the baker on a stir plate overnight to equalize the solution.
8.  Check for anaerobiosis with a BBL strip.
9.  If the solution is anaerobic, aliquot in bottles with sealable cap, and transfer out of chamber.
10.  Store the anaerobic solution in 4
oC.Zhu and Goldstein 7
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Measurement of activities of PTP1B and PTPase of cultured cells under anaerobic environment
Cell Culture and cell differentiation
3T3-L1 cell culture and differentiation:
1.  3T3-L1 pre-adipocytes are maintained in Dulbecco’s modified Eagle’s medium (DMEM) / Ham’s F12 medium (1:1)
supplemented with 10% (v/v) fetal calf serum. Never let the cells grow to confluence for passing or seeding.
2.  Cells are seeded in 10cm culture dishes and the medium is changed every other day.
3.  When cells become confluent, change medium and let cells grow two more days.
4.  Cell differentiation is induced at 2 days post confluence with medium supplemented with 100 nM insulin, 0.25 µM
dexamethasone, and 0.5 mM isobutylmethylxanthine (IBMX).
5.  After 2 days, change medium with 100 nM insulin every other day for an additional 6 days.
6.  Prior to use, the cells are serum-starved in medium containing 0.1% (w/v) bovine serum albumin (BSA) for 16 hours.
Human HepG2 cell culture:
1.  Human HepG2 cells are maintained in Eagle’s Minimal Essential Medium (EMEM) supplemented with 10% (v/v) fetal
calf serum and 1x each of non-essential amino acids and L-glutamine (Cellgro).
2.  Cells are used at 80% confluence, after 16 hours of serum starvation in medium containing 0.5% (w/v) BSA.
Cell and Tissue Fractionation
Solutions:
1.  Homogenization buffer (deoxygenized)
150 mM NaCl
5 mM EDTA
5 mM EGTA
50 mM Hepes, pH 7.5
 protease inhibitor cocktail (Sigma)
2.  Solubilization buffer (deoxygenized)
Homogenization buffer +1% (v/v) Triton X-100
Preparation of lysates:
For cultured cells
1.  Pour liquid N2 in each of 10 cm culture dishes to pulverize cells after serum-starvation.
2.  Transfer cells into the interchange and run an automatic transfer cycle.
3.  Move dishes into the anaerobic chamber and add 1 ml of ice-cold homogenization buffer for each 10 cm culture dish after
liquid N2 is evaporated.
4.  Harvest cells with cell lifter and transfer cells in 1.5 ml Eppendorf tube.
5.  Cells were sonicated briefly inside the anaerobic chamber.
Fractionation procedures
1.  The cell and tissue lysates were transferred into centrifuge tubes with air-tight lids and centrifuged at 100,000 x g for 45
min at 4
oC.
2.  Transfer tubes into the chamber and save the supernatants as the cytosol fractions.
3.  The pellets were incubated in solubilization buffer on ice for 45 min.
4.  Centrifuge at 15,000 x g for 20 min at 4
oC.
5.  Transfer tubes into the chamber and save the supernatants as the soluble particulate fractions.
6.  Protein was measured using the method of Bradford.
Immunoprecipitation of PTP1B
1.  Working within the chamber, take 500 µg protein of whole cell lysates or fractionations and normalize into 1µg/µl in 0.5
ml in 2 ml tubes with air-tight O-ring sealed lids (Fisher Scientific, catalog #05-669-4).Zhu and Goldstein 8
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2.  Add 2 µl of non-immune IgG and 20 µl of trisacryl protein G (50% beads) for  pre-clearing and incubate at 4
oC with
rolling for 1 hour.
3.  Briefly spin down the beads and transfer the samples back into the chamber.
4.  Transfer the supernatants into a set of fresh tubes and add 2 µg of anti-PTP1B antibody (Ab-2, Oncogene Sciences), a
monoclonal antibody directed at a C-terminal epitope of the enzyme that preserves its enzymatic activity.
5.  Incubate at 4
oC with rolling overnight.
6.  Transfer samples into the chamber and add 50 µl of trisacryl protein G.
7.  Continue to incubate at 4
oC with rolling for two hours.
8.  Centrifuge briefly and remove supernatants in the chamber.
9.  Wash beads with ice-cold PBS three times and the sample are ready for PTP-1B activity assay by pNPP method.
PTPase Enzyme Activity Using pNPP as Substrate
Solution:
Reaction buffer (deoxygenized):
10 mM of para-nitrophenylphosphate (pNPP, sigma)
2 mM EDTA
20 mM 2-(N-Morpholino) ethanesulfonic acid (MES) at pH 6.0,
1-2 mM DTT
No DTT for non-reducing reaction buffer
Stopping buffer:
0.2 M NaOH
Procedures:
1.  Add reaction buffer to sample for total volume of 100 µl and mix.
2.  For cell lysates, incubate at 30
oC incubator or water bath for 10 min to 2 hours inside the chamber. For
immunoprecipitated enzymes, incubate at 37
oC incubator or water bath for 10 min to 2 hours inside the chamber.
3.  Terminate the reaction by adding 900 µl of stopping buffer.
4.  The absorption was determined at 410 nm.
5.  The initial rate of pNPP hydrolysis was estimated from the linear portion of the earliest time points of the enzymatic
reaction.
6.  Enzyme activity is calculated from the molar extinction coefficient for phenyl phosphate = 1.78 x 10
4 M
-1 cm
-1 (Pot et al.
J. Biol. Chem. 1991;266:19688-19696).
PTPase Enzyme Activity Using [
32P]-RCM-Lysozyme as Substrate:
Reagents:
Reduced carboxamidomethylated and maleylated (RCM) –lysozyme
partial purified recombinant human insulin receptor
[γ-
32P]ATP (~200 cpm/pmol)
Solutions:
RCM-lysozyme phosphorylation buffer:
40 mM imidazole hydrochloride, pH 7.6
50 mM NaCl
12 mM magnesium acetate
4 mM MnCl2
100 uM ammonium molybdate
0.1 mM Na Vanadate
30 mM N-acetylglucosamine
0.2% deoxycholate
0.2 mM EGTAZhu and Goldstein 9
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0.05% Triton X-100
3% glycerol
2 mM dithiothreitol (DTT)
300 nM insulin
Phosphatase assay buffer (deoxygenized):
50 mM HEPES, pH 7.0
2 mM EDTA,
25 mM imidazole hydrochloride, pH 7.2
1 mg/ml fatty acid- and globulin-free BSA
Buffer is prepared with and without added 1-2 mM DTT
Acidic charcoal mixture:
0.9 M NaCl
90 mM sodium pyrophosphate
2 mM NaH2PO4
4% (v/v) Norit A activated charcoal
Procedures:
RCM-lysozyme phosphorylation (preparation of substrate):
1.  Add 0.5 ml of RCM-lysozyme phosphorylation buffer to an 1.5 ml tube
2.  Add 400 µg partial purified recombinant human insulin receptor
3.  Add 4 mM [γ-
32P]ATP (~200 cpm/pmol)
4.  Add 1 mg RCM-lysozyme to initiate the reaction
5.  Incubate at 30
oC overnight
6.  Add 100% Trichloroacetic acid (TCA) to a final concentration of 10% to terminate reaction
7.  Incubate on ice for 30 min
8.  Centrifuge at 27,000 x g for 15 min at 4
oC
9.  Discard the supernatant
10.  Wash the protein pellet three times further with 20% TCA to remove [γ-
32P]ATP
11.  Resuspend the pellet in 1 ml of 2 M Tris base, using a glass rod.
12.  Leave the resuspended solution on ice overnight
13.  Dialyze the sample against 50 mM imidazole hydrochloride, pH 7.2
14.  Count 10 µl of sample by Cerenkov counting in a liquid scintillation counter.
Assay of PTPases:
The assay is based on the release of [
32P]Pi from phosphorylated protein substrate (labeled RCM-lysozyme) and is performed in the
anaerobic chamber. The initial rate of RCM-lysozyme hydrolysis was estimated from the linear portion of the earliest time points
of the enzymatic reaction where less than 20% of the RCM-lysozyme was hydrolyzed. For blank control the PTPases sample is
replaced by phosphatase assay buffer and the counts are less than 2% of total radioactivity in the assay.
1.  Transfer samples, phosphatase assay buffer, substrate in a radioisotope-protective rack into the anaerobic chamber
2.  Add 0.02 ml samples containing 30 µg proteins to 1.5 ml centrifuge tubes
3.  Add 0.02 ml of phosphatase assay buffer
4.  Preincubate at 30
oC for 5 min
5.  Add the substrate (>10,000 dpm)
6.  For cell lysates, incubate at 30
oC for 10 min to 2 hours inside the chamber. For immunoprecipitated enzymes,
incubate at 37
oC for 10 min to 2 hours.
7.  Add 0.9 ml acidic charcoal mixture to terminate reactions
8.  Transfer the reaction out of the chamber
9.  Freeze briefly to facilitate the precipitation of protein
10. Thaw and centrifuge at 12,500 g for 5 min
11. The amount of radioactivity in 0.4 ml of supernatant was measured by Cerenkov counting in 5 ml liquid scintillation
counter.